Plunkett's Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunkett's Biotech & Genetics Industry Almanac 2013

PLUNKETT'S BIOTECH & GENETICS INDUSTRY TRENDS & STATISTICS 2013

Key Features:

-Industry trends analysis, market data and competitive intelligence
-Market forecasts and Industry Statistics
-Buyer may register for access to search and export data at Plunkett Research Online

Pages: 77
Statistical Tables Provided: 18
Geographic Focus: Global

A condensed market research report excerpted from Plunkett’s Biotech & Genetics Industry Almanac 2013, including forecasts and market estimates, technologies analysis and vital statistical tables. You will gain significant insights that can help you shape your own strategy for business development, product development and investments.

-How is the industry evolving?
-How is the industry being shaped by new technologies?
-How is demand growing in emerging markets and mature economies?
-What is the size of the market now and in the future?

Contents, Statistics, Forecasts and Analysis Include:

Major Trends Affecting the Biotech & Genetics Industry

1) The State of the Biotechnology Industry Today
2) A Short History of Biotechnology
3) Ethanol Production Soars, But U.S. Federal Subsidy in Question
4) Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms
5) From India to Singapore to China, Nations Compete Fiercely in Biotech Development
6) Clinical Trials and Medical Records Processing Conducted Abroad Spark Concerns
7) Gene Therapies and Patients’ Genetic Profiles Promise a Personalized Approach to Medicine
8) Breakthrough Drugs for Cancer Treatment—Many More Will Follow
9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues
10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age
11) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce
12) Breakthrough New Drug Delivery Systems Evolve
13) Stem Cells—Multiple Sources Stem from New Technologies
14) Government Support for Stem Cell Research Evolves
15) Stem Cells—Therapeutic Cloning Techniques Advance
16) Stem Cells—A New Era of Regenerative Medicine Takes Shape
17) Nanotechnology Converges with Biotech
18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise
19) Focus on Vaccines
20) Technology Discussion—Genomics
21) Technology Discussion—Proteomics
22) Technology Discussion—Microarrays
23) Technology Discussion—DNA Chips
24) Technology Discussion—SNPs (“Snips”)
25) Technology Discussion—Combinatorial Chemistry
26) Technology Discussion—Synthetic Biology
27) Technology Discussion—Recombinant DNA
28) Technology Discussion—Polymerase Chain Reaction (PCR)

Biotech & Genetics Industry Statistics

1) Biotech Industry Overview
2) The U.S. Drug Discovery & Approval Process
3) U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2011
4) U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals:1993-2011
5) Employment in Life & Physical Science Occupations, U.S.: May 2011
6) Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2011-2013
7) U.S. Exports & Imports of Pharmaceutical Products: 2007-1st Quarter 2012
8) U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2006-2021
9) U.S. Prescription Drug Expenditures: 1970-2021
10) Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2011
11) Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2011-2013
12) Global Area of Biotech Crops by Country: 2011
13) Biologics & Biotechnology R&D, PhRMA Member Companies: 2010
14) Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2011
15) Sales By Geographic Area, PhRMA Member Companies: 2010
16) Domestic U.S. Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2010
17) Domestic Biopharmaceutical R&D Scientific, Professional & Technical Personnel by Function, PhRMA Member Companies: 2010
18) Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1975-2011